100 Reasons for a World Free of Pain

One in five people live with chronic pain*

They’re our family, our friends, the people we work with every day. Their experiences are among our 100 reasons for a World Free of Pain. Their stories drive us forward every day and remind us why our vision matters. The efforts of our teams across Grünenthal help us move faster toward better treatments – and toward giving pain patients back the freedom pain has taken away from them.

* Treede RD, et al. Pain 2015 Jun; 156(6):1003-1007.

When pain takes over

How pain disrupts lives – and why empathy matters more than we think

Pain can arrive gradually – or strike without warning. And when it does, it can reshape a person’s entire life. It can limit mobility, restrict routine activities, have an impact on whether a person can follow through with plans. Most of all, it leaves people feeling overwhelmed by even the simplest tasks. And thoroughly helpless.

Magdalena Poznanski is Director Integration & Alliances at Grünenthal. Several years ago, she woke up with stiff joints, unable to even open a toothpaste tube. “It was terrifying,” she remembers. Pain medication lifted the weight that pain leaves on so many patients. “But it came with so many side effects,” she says.

Samir Sabbah, Head of Internal Manufacturing Quality DACH, could barely get himself to the hospital when one night he woke up with a terrible pain in his knee. A pain so intense he couldn’t help but cry, and he collapsed when doctors tried to X-ray his leg. “It made me feel completely helpless,” he remembers. “You can’t do anything.”
Moments like these show how pain can quickly take control and turn life upside down.

“Pain can be isolating. It affects the freedoms you have, the life decisions you make, the career you choose, the vacations you do.”

Noemi Lewald
People & Organisational Development Manager

For others, pain can become isolating. And that’s not so much because people don’t care, but because they don’t always understand. Noemi Lewald, People & Organisational Development Manager, supports a family member with chronic pain in their foot that started at a young age. When friends asked about going out for a dance, on a hike, the family member wasn’t able to join as they used to before. And at some point, friends stopped asking. “They can’t join certain activities, and suddenly they’re left out – even if it’s unintentional.” A heartbreaking situation she had to witness.

Pain is invisible and the emotional toll that comes with it often goes unnoticed by the environment: cancellations, quiet endurance, the struggle to still keep up appearances. For those living with pain, these moments shape their daily reality.

Pain goes beyond physical experiences

Pain means physical limitations, but it also often carries an emotional weight. Many people describe feeling powerless when medication doesn’t work as expected or when the cause of their pain remains unclear. “I started wondering if this is how my life will be from now on,” Magdalena explains. “It felt like a dead end.”

“It’s a privilege to work in a place where we can truly help people. When you’ve been ill yourself, you know the fears that come with it and how much every bit of support matters.”

Samir Sabbah
Head of Internal Manufacturing Quality DACH

It takes effort to regain control

Every pain patient and every pain story is different. What most have in common is the experience of losing control and the effort it takes to regain even a part of it. Magdalena relied on medication for some years and adjusted her lifestyle to keep her symptoms in check. Pain medication also helped Samir’s knee pain. Until this day no one knows where it came from – and it never came back. Noemi’s family member relies on pain medication which helped them create a happy life.

Whether through lifestyle adjustments, medication, or emotional support from others, each person found ways to cope. But their experiences changed the Grünenthal employees. They all speak about a deeper understanding for patients who live with pain every day. They know how exhausting it is, how frightening it can feel, and how urgently we need even better solutions. Solutions, that our R&D teams work on every day in identifying new effective molecules that could become tomorrow’s pain therapies.

Fascination for research and innovation

On the hunt: Finding molecular keys that can unlock relief in the human body

Our motivation? Making lives better! Living with chronic pain feels like carrying an invisible weight. It impacts everything – patients’ routines, their mental health, their relationships. It’s a daily battle that requires resilience, often reshaping how those affected interact with the world – and how the world interacts with them.

Our R&D teams work for a future where pain no longer limits anyone’s life. This includes developing innovative therapies for people whose pain has not been relieved by existing treatments. It’s lasting change over temporary comfort that empowers patients to regain control over their lives.

“The likelihood of a molecule from my lab reaching a pharmacy is very low, but the ultimate drive is knowing it could one day help people.

That’s my greatest motivation.

Stefanie Ritter
Head Innovation Chemistry Laboratory

Understanding pain
is the foundation of our work

Every molecule that we create in our labs could be the breakthrough that passes all trials and regulatory hurdles, ends up in a medicine and helps a person hoping for relief. Before we can find those molecules, we must understand the pathophysiology of pain. And when we develop treatments, we must appreciate that pain is a very subjective experience. “Chronic pain studies are extremely challenging because so much depends on subjective perception,” explains Katrin Fleischer, Head Global Regulatory Strategy. It cannot be simply measured on a scale. It’s a complex biological and emotional experience that varies from person to person. Understanding how pain works in the body and how it affects people’s daily lives is essential. It demands curiosity, patience, and deep scientific insight.

Learn more about the fundamentals of pain.

We follow a holistic approach to understanding pain, building our programmes on a firm foundation of human pathophysiology and human target validation. We reinforce our internal innovation capabilities through long-term R&D partnerships with leading institutions around the globe, always seeking to strengthen and expand our network of leading scientists. With our Innovation Hub, we have established a centre of excellence for pain research in Boston, one of the world’s most vibrant biotech communities. What guides us is simple: patients’ needs.

“We don’t have enough medications to adequately treat everyone with chronic pain, which is why our continued efforts are essential.”

Katrin Fleischer
Head Global Regulatory Strategy

Finding new substances is our biggest challenge

The search for new substances is a hunt for precision. Our teams work like molecular key makers, trying to craft the exact structure that fits the right biological lock. “It’s like searching for a needle in a haystack,” says Stefanie Ritter. Our Head Innovation Chemistry Laboratory and her team break molecules apart and rebuild them in new ways, refining them again and again. Many molecules fall short. For Stefanie, every attempt means getting one step closer to the one molecule that will change lives for the better.

“Securing a consistent supply of human tissue and cells, and leveraging AI to automate processes and minimise human error and variability, was a significant leap forward in our efforts.”

Omar Mossad
Disease Biology Scientist

New ideas and cutting-edge technologies drive innovation

Innovative technologies are transforming how we approach pain research. One breakthrough is the integration of AI‑enabled image analysis. Instead of manually examining microscopic images – a process that used to take days – AI helps our teams identify structures and extract information in just hours. “AI has been a huge leap forward,” Omar Mossad, Disease Biology Specialist, explains. “It allows us to analyse more data more precisely and uncover patterns we could never see manually.”

Human validation remains crucial when it comes to researching molecules. Omar and his team study primary human cells and tissue samples from human donors early in development. “This helps us see what truly happens inside the human body”, he says. Such an approach mirrors the human organism, bringing the potential for faster and more relevant medical advances, bypassing often unreliable results from non-human models. In doing so, it reduces our reliance on animal models, paving the way for faster, more ethically-aligned pathways to create patient-ready medicines.

Genetic medicine helps influence the root cause of pain

With advancements in genetic medicine, we are building new capabilities, including laboratories dedicated to synthesising oligonucleotides, a key element in RNA therapeutics. Binding to a particular sequence of human messenger RNA complementary to their own structure, they can be used to reduce the production of a specific protein and thus mitigate its undesired effects. One of the advantages of oligonucleotides is their precision. When optimised, they only influence the production of the one protein we want to manipulate and no other protein in the human body. A single oligonucleotide comprises a series of individual building blocks, often 21-23 bases in number, which must be created and joined together in a series of chemical reactions.

Turning molecules into medicine

Finding the right molecule is only the beginning. The path from the lab to pharmacy shelves is long and demanding, shaped by strict regulatory requirements and countless scientific decisions. Every step must hold up to scrutiny, because each data point ultimately determines whether a therapy will reach a patient. “Regulators are people, too,” says Katrin Fleischer, Head of Global Regulatory Strategy. “They need a clear, convincing story in a sea of data. Our job is to present the evidence in a way that shows exactly how a new medicine can help patients and to push boundaries wherever the science allows.”

This is why discovering new substances at Grünenthal means working with precision, strategy, and a constant focus on the best outcome for patients. Finding a molecule and translating it into real-world therapy is our dedication and moves us closer to a World Free of Pain.

Meet our experts

Always exploring the latest science

R&D teams at Grünenthal are at the forefront of scientific progress within the pharmaceutical industry.

Our experts investigate ways for new technologies to open up transformative treatment options for patients. From leveraging single-cell methodologies through to unleashing the power of AI to accelerate our research activities, we are always embracing the possibilities of future-facing science.

Cross-functional work for better outcomes

Why collaborating teams speed up progress and bring better solutions to patients

Cross-functional work brings together people who think differently, speak differently, work differently, and transform all those differences into something stronger. Their shared purpose of working for a World Free of Pain is what makes Grünenthal employees get up in the morning. “What inspires me every day is that everyone is working for the same purpose,” says Madalena Carvalho, Controlling Business Partner IT. “Even though we come from completely different departments, we are all contributing to helping patients.”

Her experience illustrates how collaboration leads to better decisions. Finance, she says, is far more than spreadsheets. “Everything that’s in the numbers is related to the patients,” Madalena explains. “But you only understand the full picture when you work together.”

Others value the deep learning that emerges when different disciplines, cultures and experiences tackle a challenge. From scientists, engineers and HR colleagues to commercial teams, global operations, and many more. “Cross‑functional work teaches you so much,” says Magdalena Poznanski, Director Integration & Alliances. “You learn how the company really works, how decisions take shape, and how many puzzle pieces you need to move something forward.”

“Working cross-functionally made me more resilient, more pragmatic, and better at finding real solutions.”

Madalena Carvalho
Controlling Business Partner IT

Cross-functional work brings variety and healthy complexity. For Noemi Lewald, People & Organisational Development Manager, this diversity of viewpoints is part of the appeal. “In global projects, every country has an opinion, sometimes thirty,” she says laughing. “That diversity challenges you in the best way.” And it improves the outcome of projects.

Different cultures, expectations, and communication styles shape these collaborations. Xichao Zhou, Business Process Owner Demand Planning, sees this as a strength rather than a barrier. “I come from China, and there, efficiency is everything. But working internationally taught me the value of alignment and relationships. Understanding both leads to better solutions.”

Colleagues also say the emotional side of collaboration can be transformative. “In the beginning, I took things very personally,” Noemi recalls. “But learning to listen first to understand where people are coming from has made me better at my job.”

Some roles face spikes during critical phases, yet teamwork turns these moments into shared wins. “Knowing everyone is pulling in the same direction makes even intense phases manageable”, says Magdalena Poznanski, Director Integration & Alliances.

“Everything we do,
we do for the patients.”

Magdalena Poznanski
Director Integration & Alliances

Real progress begins when people come together with a shared purpose. At Grünenthal, that purpose is deeply human: easing the lives of people living with pain. It’s our colleagues’ different backgrounds, expertise and experiences that enrich conversations and help people understand each other better.

We all know, that only then solutions take shape that none of us could create alone. These connections don’t stay within our walls. They reach every person who depends on our work. Learning from another and joining forces across teams means we make better decisions.

This ultimately shortens development timelines, improves decision‑making, and strengthens the quality of the medication we deliver. For us, joining forces is the only way to achieve a World Free of Pain.

“What really matters is how much we have been able to help other people live better lives.”

Mariángeles Caro Cabello
Sales Manager

My partner’s slipped disc showed me how our therapies can bring people back to life.”

Karsten Langohr
Group Accountant

“I’m fascinated by finding out more and more about how we can combat pain in a targeted manner.”

Ramona Schrage
Head of Primary Pharmacology Laboratory

“I’m proud to be at the forefront of developing new RNA pain therapies with Grünenthal.

Keith Philips
Head of Genetic Medicine

“Our commitment to making pain more manageable is more than just a slogan; it’s personal.

Magdalena Poznanski
Director Integration & Alliances

“I work towards a future where personalised pain medicine is a reality.

Andrew Lockhart
Head Translational and Disease Understanding Unit

“The work we do can significantly affect an individual, and that’s what makes it exceptionally meaningful to me.

Laura Wasser
Sourcing Manager DACH

“Given the complexity of our healthcare systems, making pain treatment more accessible to patients is a very fulfilling task.

Loi Vo
National Market Access Manager

Imprint.

Contact

Matt Crabb
Head of Global Communications (Interim)
E-mail: GlobalCommunication@grunenthal.com

Photo Credits

Grünenthal, Image Professionals GmbH, Adobe Stock, Getty Images, Magnific/Freepik Company

Disclaimer
Privacy

Publisher

GRÜNENTHAL PHARMA GMBH & CO. KG
Zieglerstrasse 6
52078 Aachen
Germany

Phone: +49 241 569 0
E-mail: info@grunenthal.com
www.grunenthal.com